Trial Profile
A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Palifermin (Primary) ; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Filgrastim; Filgrastim; Fludarabine; Furosemide; Mesna; Methotrexate; Prednisone; Rituximab; Sirolimus; Tacrolimus; Tacrolimus; Vincristine
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 17 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Dec 2025.
- 17 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Dec 2025.
- 12 Dec 2023 Results assessing alterations in immune cell reconstitution and cytokine expression among patients from the TMS and DL1 groups (6/8 tested patients with any AGVHD II-IV) presented at the 65th American Society of Hematology Annual Meeting and Exposition